摘要
【目的】评估并比较左舒必利、多潘立酮和胃复安三种不同药物治疗功能性消化不良的安全性及临床疗效。【方法】选取2014年6月至2015年3月于本院确诊为功能性消化不良患者150例;随机分为三组;每组各50例。三组患者分别接受左舒必利、多潘立酮和胃复安药物治疗。利用利兹消化不良问卷及李克特五点量表法评估患者治疗前后的功能性消化不良症状程度。【结果】150例患者中;有143例患者(左舒必利组50例、多潘立酮组45例和胃复安组48例)成功完成本试验。三种药物都能不同程度改善患者的功能性消化不良症状;但左舒必利组患者消化不良症状的总体改善程度显著高于其他两组(P<0.05);且患者不良反应(包括恶心、头痛、腹泻等)的发生率最低。【结论】左舒必利相对于多潘立酮和胃复安在治疗功能性消化不良方面具有更高的安全性及疗效。
【Objective】 To evaluate and compare the safety and clinical efficacy of levosulpiride, domperidone and metoclopramide in the treatment of functional dyspepsia.【Methods】 One hundred and fifty patients with functional dyspepsia from June 2014 to March 2015 were randomly divided into three groups with 50 cases in each group. The three groups were treated with levosulpiride, domperidone and metoclopramide respectively. The degree of functional dyspepsia before and after treatment was evaluated by Leeds indigestion questionnaire and Likert five-point scale. 【Results】 143 of 150 patients (50 in the levosulpiride group, 45 in the domperidone group and 48 in the metoclopramide group) completed the test successfully. All three drugs can improve patients' symptoms of functional dyspepsia to varying degrees. However, the overall improvement of dyspepsia in the levosulpiride group was significantly higher than that in the other two groups (P<0.05), and the incidence of adverse reactions (including nausea, headache, diarrhea, etc.) was the lowest in the levosulpiride group.【Conclusion】 Levosulpiride has higher safety and efficacy than domperidone and metoclopramide in the treatment of functional dyspepsia.
作者
魏铁军
张恒
郭艺静
张永利
姜萌
白云磊
WEI Tie-jun;ZHANG Heng;GUO Yi-jing(Department of Digestive Medicine,the SunSimiao Hospital,Beijing University of Traditional Chinese Medicine, Tongchuan 727000)
出处
《医学临床研究》
CAS
2018年第12期2332-2334,共3页
Journal of Clinical Research
